Company intelligence / Profile preview

FACT

Ownership: Private
Development stage: Other

Overview

FACT Biotech is a precision medicine company focused on developing next-generation cell therapies for solid tumors. The company utilizes its proprietary Functional Analysis of Cell Targets (FACT) platform to identify and validate novel T-cell receptor (TCR) targets that are highly specific to cancer cells. By leveraging advanced screening technologies, FACT Biotech aims to overcome the challenges of target heterogeneity and off-target toxicity in oncology. Their pipeline is primarily focused on TCR-engineered T-cell therapies designed to provide durable responses in patients with difficult-to-treat cancers.

Therapeutic areas: Oncology
Modalities: Cell therapyT cell receptor engineered T cell therapyCAR-T cell therapy
Industry: Biotech

Beyond the preview

Go deeper on FACT.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FACT.

Explore the full profile